Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The North American Spine Society (NASS) has revised its coverage recommendations for rhBMP-2, a bone-forming protein used in spinal fusion surgery. The updated guidelines now specifically support its use in adult patients at high risk for nonunion — including smokers, diabetics, and those undergoing revision surgeries. The shift moves away from a blanket standard toward a more targeted, risk-stratified approach.
The North American Spine Society (NASS) has updated its coverage recommendations for recombinant human bone morphogenetic protein-2 (rhBMP-2), a biologic used to stimulate new bone growth during spinal fusion surgery. The revised guidelines, grounded in original FDA investigational studies and a 2013 independent reanalysis of patient data, now explicitly support rhBMP-2 as an adjunct in posterolateral and transforaminal lumbar interbody fusion — but only for adult patients at elevated risk for nonunion.
The new framework marks a meaningful shift from the previous 2014 "when alternatives aren't available" standard. Instead, it calls for documented risk stratification before use, which is expected to reshape both patient consent conversations and prior authorization workflows.
Key Takeaways:
Why it matters: These updated guidelines give spine surgeons clearer, evidence-based criteria for when rhBMP-2 is appropriate — reducing ambiguity in coverage decisions while pushing for more personalized, risk-informed care.
